Related Experiment Videos
Lovastatin therapy for cholesterol ester storage disease in two sisters
M D Tarantino1, D J McNamara, P Granstrom
1Department of Pediatrics, University of Arizona Health Sciences Center, Tucson.
The Journal of Pediatrics
|January 11, 1991
Summary
Lovastatin effectively treated two sisters with cholesterol ester storage disease, significantly lowering their cholesterol and triglyceride levels. The treatment also reduced liver fat content and hepatic cholesterol stores.
Area of Science:
- Biochemistry
- Pharmacology
- Genetics
Background:
- Cholesterol ester storage disease (CESD) is an autosomal recessive disorder.
- CESD presents with hypercholesterolemia and hypertriglyceridemia.
- Pediatric hyperlipidemia requires effective therapeutic strategies.
Observation:
- Lovastatin, a HMG-CoA reductase inhibitor, was administered orally to two pediatric patients with CESD.
- Treatment duration was six months with monthly lipid monitoring.
- Liver fat content was assessed via computed tomography and liver biopsies.
Findings:
- Both patients exhibited significant reductions in serum cholesterol, triglycerides, and LDL-cholesterol.
- HDL-cholesterol levels increased during lovastatin therapy.
- Computed tomography indicated decreased liver fat content, and liver biopsies showed a 13% reduction in esterified cholesterol.
Implications:
- Lovastatin demonstrates potential efficacy in managing pediatric cholesterol ester storage disease.
- This study highlights lovastatin as a therapeutic option for children with severe hyperlipidemia.
- Further research may explore long-term outcomes and optimal dosing in pediatric populations.